Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc has demonstrated successful delivery of PG-102 via oral administration with enhanced bioavailability, marking a significant advancement in the development of its RaniPill technology. The partnership with Chugai not only validates the RaniPill platform but also positions the company within a lucrative multi-billion dollar market for biologics, suggesting growth potential through strategic collaborations. Additionally, with a robust cash runway extending through 2028, Rani is well-equipped to advance its programs, potentially unlocking substantial value for shareholders while being at the forefront of innovations in oral drug delivery solutions.

Bears say

Rani Therapeutics Holdings Inc faces a negative outlook primarily due to uncertainty surrounding its revenue forecasts, which are heavily dependent on achieving specific reimbursement levels; any failure to meet these expectations could adversely impact financial projections. Additionally, there are concerns related to competition that may disrupt Rani's pipeline and future product candidates, further complicating revenue generation. While the company has demonstrated mechanical safety through an extensive dataset, the potential for failure in future clinical trials remains a significant risk to its financial viability and market valuations.

RANI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 4 analysts, RANI has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.